Biotech

Adam's Take

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

By Adam Feuerstein

Biotech

Bellus Health hopes to be one of biotech’s more improbable turnarounds

By Damian Garde

Biotech

Startup Spotlight: Carisma Therapeutics wants to make a cell therapy that will work in solid tumors

By Kate Sheridan

Biotech

Pfizer’s top-selling vaccine won’t prevent Covid-19, but could get a boost because of it

By Matthew Herper

Biotech

‘Organ-on-a-chip’ maker Emulate names new CEO, announces new funding

By Anissa Gardizy — Boston Globe

Biotech

Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?

By Maggie Fox

Adam's Take

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

By Adam Feuerstein

Biotech

Anticipating ‘shelter-in-place’ orders across the country, trade groups push for exceptions for biopharma employees

By Rebecca Robbins and Kate Sheridan

Biotech

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

By Adam Feuerstein and Matthew Herper

Biotech

Despite coronavirus disruption, major microbiome companies are cautiously optimistic about upcoming data

By Kate Sheridan

Biotech

Near-lockdown in the Bay Area ‘ratchets up’ challenges for local biotechs and labs

By Rebecca Robbins

Adam's Take

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

By Adam Feuerstein

Biotech

Merck drug reduces cough frequency but taste alterations could cloud prospects

By Adam Feuerstein

Biotech

Regeneron says potential Covid-19 drugs could start human tests by early summer

By Matthew Herper

Biotech

As the market craters, Keros Therapeutics files for an IPO

By Kate Sheridan

Biotech

Drug makers grounding salespeople as coronavirus impact on business spreads

By Adam Feuerstein

Biotech

To quell unpredictable allergic reactions, an experimental drug takes aim at a genetic cause, not symptoms

By Damian Garde

Biotech

How one company made $208 million on an untested coronavirus vaccine

By Damian Garde and Adam Feuerstein

Health

One dead, four hospitalized after receiving OpenBiome stool transplants

By Kate Sheridan

Biotech

Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers

By Anissa Gardizy — Boston Globe

Biotech

Engage touts long-awaited positive data for its inhaler for seizures

By Kate Sheridan

Health

Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals

By Eric Boodman

Biotech

Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer

By Rebecca Robbins

transmission electron micrograph covid19

Adam's Take

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

By Adam Feuerstein

Biotech

FDA rejects Intarcia’s diabetes implant for a second time

By Kate Sheridan

New drug from Merck, Bayer reduces hospitalizations for heart failure patients

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Could real-world evidence help shape the future of drug development?

What it’s like to go into the lab at a biopharma company during the coronavirus pandemic

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Bellus Health hopes to be one of biotech’s more improbable turnarounds

Startup Spotlight: Carisma Therapeutics wants to make a cell therapy that will work in solid tumors

Pfizer’s top-selling vaccine won’t prevent Covid-19, but could get a boost because of it

‘Organ-on-a-chip’ maker Emulate names new CEO, announces new funding

Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Anticipating ‘shelter-in-place’ orders across the country, trade groups push for exceptions for biopharma employees

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

Despite coronavirus disruption, major microbiome companies are cautiously optimistic about upcoming data

Near-lockdown in the Bay Area ‘ratchets up’ challenges for local biotechs and labs

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

Merck drug reduces cough frequency but taste alterations could cloud prospects

Regeneron says potential Covid-19 drugs could start human tests by early summer

As the market craters, Keros Therapeutics files for an IPO

Drug makers grounding salespeople as coronavirus impact on business spreads

To quell unpredictable allergic reactions, an experimental drug takes aim at a genetic cause, not symptoms

How one company made $208 million on an untested coronavirus vaccine

One dead, four hospitalized after receiving OpenBiome stool transplants

Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers

Engage touts long-awaited positive data for its inhaler for seizures

Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals

Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

FDA rejects Intarcia’s diabetes implant for a second time